CAM
BIO icon

Capstone Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Capstone Asset Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$906K Sell
4,005
-169
-4% -$36.8K 0.03% 621
2017
Q1 		$832K Buy
4,174
+365
+10% +$70.3K 0.02% 648
2016
Q4 		$694K Sell
3,809
-151
-4% -$25.7K 0.02% 735
2016
Q3 		$649K Sell
3,960
-440
-10% -$66.8K 0.02% 786
2016
Q2 		$629K Buy
4,400
+10
+0.2% +$1.43K 0.02% 796
2016
Q1 		$600K Buy
4,390
+530
+14% +$69.6K 0.02% 801
2015
Q4 		$535K Buy
3,860
+443
+13% +$61.4K 0.02% 879
2015
Q3 		$459K Buy
3,417
+473
+16% +$68.1K 0.01% 973
2015
Q2 		$443K Buy
2,944
+414
+16% +$59.2K 0.01% 1042
2015
Q1 		$342K Buy
2,530
+130
+5% +$16.1K 0.01% 1315
2014
Q4 		$289K Sell
2,400
-270
-10% -$31.1K 0.01% 1391
2014
Q3 		$303K Buy
2,670
+270
+11% +$32K 0.01% 1343
2014
Q2 		$287K Buy
2,400
+560
+30% +$68.4K 0.01% 1411
2014
Q1 		$236K Sell
1,840
-330
-15% -$42.3K 0.01% 1564
2013
Q4 		$268K Sell
2,170
-500
-19% -$60.9K 0.01% 1594
2013
Q3 		$314K Buy
+2,670
New +$315K 0.01% 1634

Other funds holding BIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Capstone Asset Management's BIO Position: Q2 2017 in Review

Capstone Asset Management reduced its Bio-Rad Laboratories Class A (BIO) stake by 4% in Q2 2017, selling an estimated $36.8K and leaving 4,005 shares worth $906K. The position accounts for 0.03% of the portfolio, ranked #621.

Capstone Asset Management first reported a position in BIO in Q3 2013 and has held it in 16 quarters since. 276 funds tracked by Wall St. Rank hold BIO as of Q2 2017.

  • Capstone Asset Management held 4,005 shares of Bio-Rad Laboratories Class A worth $906K as of Q2 2017.
  • Capstone Asset Management sold 169 Bio-Rad Laboratories Class A shares in Q2 2017, an estimated $36.8K.
  • Bio-Rad Laboratories Class A made up 0.03% of Capstone Asset Management's portfolio in Q2 2017, its #621 holding.
  • Capstone Asset Management first reported a position in Bio-Rad Laboratories Class A in Q3 2013 and has held it in 16 quarters since.
  • 276 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2017.

Based on Capstone Asset Management's 13F filing for Q2 2017, filed 10 Jul 2017.